All Oncology News

Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

Costs under the 340B program have ballooned far beyond earlier estimates, based on certain aspects of the program that have not been looked at closely.

Long-term aspirin use significantly lowered the risk of developing colorectal cancer in Lynch syndrome carriers while ameliorating the added risk associated with obesity.

A supplemental new drug application has been submitted for the BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia who are over the age of 65.

Sanaz Memarzadeh, MD, PhD, discusses a combination regimen of birinapant and carboplatin in patients with high-grade serous ovarian cancers and high levels of cellular inhibitor of apoptosis protein (cIAP) in their CA-125–negative cells.

Treatment with the second-generation HER2/EGFR-targeted TKI neratinib resulted in a partial response and dramatic improvement in functional status for a patient with HER2-mutated breast cancer.

Marleen Meyers, MD, discusses rolapitant (Varubi), which the FDA recently approved to prevent delayed CINV.

Alectinib received an FDA priority review designation for patients with ALK-positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib (Xalkori).

Ten-story building named for Albert P. "Skip" Viragh Jr. planned for the northeast corner of Fayette Street and North Broadway.

Jeffrey S. Weber, MD, PhD, to serve as Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone, Co-Director of its Melanoma Program and Head of Experimental Therapeutics.

The FDA has granted a priority review designation to the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma.

The FDA has assigned a priority review designation to daratumumab for heavily pretreated patients with multiple myeloma.

The European Commission has approved panobinostat in combination with bortezomib and dexamethasone for adult patients with relapsed/refractory multiple myeloma following prior treatment with bortezomib and an immunomodulatory agent.

The telomerase inhibitor imetelstat has shown encouraging signs of clinical activity in patients with myelofibrosis and essential thrombocythemia.

The first FDA-approved biosimilar, Zarxio, is now available for patients in the United States, following a series of lawsuits and court decisions.

Dennis Slamon, MD, PhD, discusses the inhibition of CDK 4/6 and PD-1, which represent two of the most exciting developments in the field of metastatic breast cancer.

Nivolumab (Opdivo) has received an FDA priority review designation for patients with previously treated nonsquamous non–small cell lung cancer.

The FDA has approved aprepitant capsules in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting in patients aged 12 to 17 and for those under the age of 12 who weigh at least 30 kg who are receiving chemotherapy.

The European Commission has approved eltrombopag as a treatment for adult patients with severe aplastic anemia who are refractory to immunosuppressive therapy or are heavily pretreated and not suitable for hematopoietic stem cell transplant.

The FDA has approved rolapitant (Varubi) for use in combination with other antiemetic agents to prevent delayed CINV.

The combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) has been approved in the EU for advanced melanoma.

OncLive today announced it is teaming up with Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to provide breaking news and information about the hospital's pioneering research and care for cancer patients. Editorial and marketing groups within OncLive, which provides oncologists resources and information they need to deliver the best care for their patients, will focus on many cancer-related programs and initiatives at Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.

The FDA has granted elotuzumab (Empliciti) a priority review for use in combination therapy in pretreated patients with multiple myeloma.

ASCO has updated their clinical practice guideline for the treatment of patients with stage IV non-small cell lung cancer, placing greater emphasis on the selection of targeted therapies.

Anna Pavlick, DO, discusses immunotherapy and targeted combination regimens in advanced melanoma.

Young women with breast cancer may decline, discontinue tamoxifen because of fertility concerns.

The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.

Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven will launch a new research program in non-small cell lung cancer, one of the world's most prevalent and lethal forms of cancer.

Sequence of therapies may be more significant versus single agents in treating patients with metastatic colorectal cancer.

Immune checkpoint inhibitors can be of significant value in combatting recurrent and metastatic triple negative breast cancer, Rita Nanda, MD, told physicians at the recent 14th Annual International Congress on the Future of Breast Cancer.